Israel-Medical-Healthcare

[genisi]

Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT

http://www.kamada.com/NewsAndEvents.asp?CurrentYear=2008&CurrentMonth=12&PRID=57

December 16, 2008

Kamada (TASE; KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics, announced today that it has completed patient enrollment in its Phase II clinical trial evaluating treatment of bronchiectasis patients with inhaled Alpha-1 Antitrypsin (AAT) delivered by the investigational eFlow nebulizer system (PARI Pharma GmbH). Chief Executive Officer of Kamada, David Tsur, said, "We are very pleased with the progress of this study and look forward to its upcoming completion. We believe that Kamadas AAT delivered by PARIs eFlow has the potential to become a novel treatment for bronchiectasis. Kamada is committed to the development of inhaled AAT to treat bronchiectasis and to proceed with its ongoing clinical efforts in Alpha 1 Antitrypsin Deficiency and Cystic Fibrosis [The company is looking to partner its inhaled program and planing to start a phase III trial in 09]
.
About the study: A total of 21 patients with brochiectasis were enrolled and randomized into this , double-blind, placebo controlled Phase II study. The purpose of the trial is to investigate safety and efficacy of inhaled AAT in this patient population.
About Kamada's Inhaled AAT...snip